If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wondered how symptoms actually present versus how doctors diagnose the condition. The legacy of drug safety monitoring has long emphasized the importance of distinguishing patient-reported symptoms from clinical diagnostic criteria. This page breaks down what the FDA label says about PML symptoms, how diagnosis is confirmed, and what that means for your care.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
PML typically occurs only in immunocompromised individuals and is caused by the JC virus. The clinical presentation can include progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed through brain imaging and detection of JC virus DNA in cerebrospinal fluid. The prognosis is poor, with the infection usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow latent JC virus to reactivate and cause infection in the brain.
The adequacy of warnings regarding Tysabri and PML is a central issue in legal claims. The prescribing information includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and understand the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, plaintiffs may argue that these warnings were insufficient to fully inform patients and healthcare providers of the magnitude of risk, particularly in the context of long-term therapy. Settlement-related considerations for affected patients often involve evaluating the timing of diagnosis, the presence of risk factors, and the extent of harm suffered. For patients in Washington, the statute of limitations for filing a Tysabri-related PML lawsuit is generally governed by state law. In Washington, the statute of limitations for personal injury claims is typically three years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML can develop months to years after starting Tysabri, and symptoms may initially be subtle. The boxed warning notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, the clock for the statute of limitations may start when the patient or their healthcare provider first recognized symptoms consistent with PML, or when a formal diagnosis was made. Delays in diagnosis can complicate the timeline, and patients should seek legal advice promptly to ensure their claim is filed within the applicable period.
In summary, Tysabri-associated PML is a severe adverse event with well-defined risk factors and a poor prognosis. The drug's labeling includes explicit warnings, but legal claims may focus on the adequacy of those warnings and the timing of harm. For Washington patients, the statute of limitations requires careful attention to the date of discovery of injury. Settlement considerations will depend on individual circumstances, including the presence of risk factors and the severity of disability. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Washington, the statute of limitations for personal injury claims is typically three years from the date the injury was discovered or reasonably should have been discovered. For Tysabri-related PML, this clock may start when symptoms consistent with PML are first recognized or when a formal diagnosis is made. It is crucial to seek legal advice promptly to ensure your claim is filed within the applicable period.
The three primary risk factors for Tysabri-associated PML are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA-approved prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.